At a glance
- Originator Bristol-Myers Squibb
- Class Osteoporosis therapies
- Mechanism of Action Proton pump inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Postmenopausal osteoporosis
Most Recent Events
- 07 Sep 1998 No-Development-Reported for Postmenopausal osteoporosis in USA (Unknown route)
- 24 Oct 1996 New profile
- 24 Oct 1996 Preclinical development for Postmenopausal osteoporosis in USA (Unknown route)